Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + anlotinib combined with radiotherapy for unresectable primary hepatocellular carcinoma
ChiCTR2000031183Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in hepatocellular carcinoma (HCC), sponsored by Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031183.